Komori
Cota (4923) · InitiativeReframed

Hair-Growth Research and Safety Assessment Without Animal Testing

First written in FY2016. 22 of 30 entries say "Restated". Latest entry: FY2026.

30entries
11years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2018-Q1 – FY2019-Q3RestatedFY2020-Q1 – FY2022-Q3RestatedFY2023-Q1 – FY2024-Q3AdvancedFY2024 – 2026-06-112016: 320162017: 420172018: 320182019: 420192020: 320202021: 320212022: 420222023: 120232024: 220242025: 120252026: 22026
Same theme, other companies
Commercialization and Standardization of Hair Regenerative Medicine and Alternatives to Animal TestingA theme 2 companies write about · 0 as a headwind · 2 as a tailwind

0 other companies' latest entry also says "Reframed".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026ReframedAnnual report

    「① Clarifying the effects of surfactants on scalp itching and researching methods for reducing it ② Establishing methods for evaluating hair damage caused by multiple factors and researching methods for suppressing such damage」

    The priority areas in basic research have been organized to include the mechanism and reduction of surfactant-induced itching, as well as the evaluation and suppression of multifactorial hair damage caused by bleaching, ultraviolet radiation, and other factors.
  2. 2026-06-11AdvancedOther Disclosures

    「We intend to use the knowledge gained from this patent in the development of new hair-care products that help suppress hair hardening and deterioration in feel caused by glycation and oxidation.」

    Research on glycation and oxidation in hair has progressed to the acquisition of patent rights for an agent that suppresses glycation and oxidation damage and plans to use the findings in new hair-care products.
  3. FY2025AdvancedAnnual report

    「The company obtained a patent for a method of reducing itching and presented its research results at the 62nd Annual Meeting of the Japan Oil Chemists' Society.」

    The company obtained a patent and made a conference presentation on research into reducing scalp itching caused by surfactants, and also presented its research on the aging of hair and the scalp at the 29th Glycation Stress Research Society meeting. Research and development expenses were ¥509 million.
  4. FY2024AdvancedAnnual report

    「① The effects of surfactants on scalp itching and methods for reducing it ② Establishing methods for measuring the physical properties associated with the aging of hair and the scalp」

    The company continued its 2 priority areas in basic research, and presented its surfactant research at the IFSCC Congress 2023. Research and development expenses were ¥507 million.
  5. FY2024-Q3RestatedAnnual report

    「Total research and development expenses for the cumulative third-quarter period were ¥382 million. There were no material changes in the status of the company's research and development activities during the cumulative third-quarter period.」

    The company stated that there were no material changes in its research and development activities and disclosed research and development expenses of ¥382 million for the cumulative third-quarter period.
  6. FY2024-Q1RestatedAnnual report

    「Total research and development expenses for the cumulative first-quarter period were ¥129 million. There were no material changes in the status of the company's research and development activities during the cumulative first-quarter period.」

    The company stated that there were no material changes in its research and development activities and disclosed ¥129 million in research and development expenses.
  7. FY2023-Q2RestatedAnnual report

    「Total research and development expenses for the cumulative second-quarter period were ¥287 million. There were no material changes in the status of the company's research and development activities during the cumulative second-quarter period.」

    The company stated that there were no material changes in its research and development activities and disclosed research and development expenses of ¥287 million for the cumulative second-quarter period.
  8. FY2023-Q1RestatedAnnual report

    「Total research and development expenses for the cumulative first-quarter period were ¥167 million. There were no material changes in the status of the company's research and development activities during the cumulative first-quarter period.」

    The company stated that there were no material changes in its research and development activities and disclosed ¥167 million in research and development expenses.
  9. FY2022ReframedAnnual report

    「The current priority areas in basic research are the following 2: research, with the cooperation of external research institutions and universities, into ① the effects of surfactants on hair and ② establishing methods for measuring the physical properties associated with the aging of hair and the scalp.」

    The priority areas in basic research have been organized into 2 areas: confirming the effects of surfactants on hair and physical-property assessment related to the aging of hair and the scalp.
  10. FY2022-Q3RestatedAnnual report

    「Total research and development expenses for the cumulative third-quarter period were ¥326 million. There were no material changes in the status of the company's research and development activities during the cumulative third-quarter period.」

    The company stated that there were no material changes in its research and development activities and disclosed ¥326 million in research and development expenses.
  11. FY2022-Q2RestatedAnnual report

    「Total research and development expenses for the cumulative second-quarter period were ¥214 million. There were no material changes in the status of the company's research and development activities during the cumulative second-quarter period.」

    The company stated that there were no material changes in its research and development activities and disclosed ¥214 million in research and development expenses.
  12. FY2022-Q1RestatedAnnual report

    「Total research and development expenses for the cumulative first-quarter period were ¥106 million. There were no material changes in the status of the company's research and development activities during the cumulative first-quarter period.」

    The company stated that there were no material changes in its research and development activities and disclosed research and development expenses of ¥106 million for the cumulative first-quarter period.
  13. FY2021-Q3RestatedAnnual report

    「Total research and development expenses for the cumulative third-quarter period were ¥308 million. There were no material changes in the status of the company's research and development activities during the cumulative third-quarter period.」

    The company stated that there were no material changes in its research and development activities and disclosed research and development expenses of ¥308 million for the cumulative third-quarter period.
  14. FY2021-Q2RestatedAnnual report

    「Total research and development expenses for the cumulative second-quarter period were ¥206 million. There were no material changes in the status of the company's research and development activities during the cumulative second-quarter period.」

    The company stated that there were no material changes in its research and development activities and disclosed research and development expenses of ¥206 million for the cumulative second-quarter period.
  15. FY2021-Q1RestatedAnnual report

    「Total research and development expenses for the cumulative first-quarter period were ¥102 million. There were no material changes in the status of the company's research and development activities during the cumulative first-quarter period.」

    The company stated that there were no material changes in its research and development activities and disclosed research and development expenses of ¥102 million for the cumulative first-quarter period.
  16. FY2020RestatedAnnual report

    「The current priority areas in basic research are the following 3: research, with the cooperation of external research institutions and universities, into ① the effects of nanomaterials on hair, ② the effects of surfactants on hair, and ③ establishing methods for measuring the physical properties associated with the aging of hair and the scalp.」

    The company continued basic research into nanomaterials, surfactants, and the aging of hair and the scalp, and research and development expenses for the fiscal year were ¥393 million.
  17. FY2020-Q2RestatedAnnual report

    「Total research and development expenses for the cumulative second-quarter period were ¥187 million. There were no material changes in the status of the company's research and development activities during the cumulative second-quarter period.」

    The company recorded ¥187 million in research and development expenses and stated that there were no material changes in its research and development activities.
  18. FY2020-Q1RestatedAnnual report

    「Total research and development expenses for the cumulative first-quarter period were ¥92 million. There were no material changes in the status of the company's research and development activities during the cumulative first-quarter period.」

    The company recorded ¥92 million in research and development expenses and stated that there were no material changes in its research and development activities.
  19. FY2019ReframedAnnual report

    「The current priority areas in basic research are the following 3: research, with the cooperation of external research institutions and universities, into ① the effects of nanomaterials on hair, ② the effects of surfactants on hair, and ③ establishing methods for measuring the physical properties associated with the aging of hair and the scalp.」

    The focus of basic research has been organized and changed from conventional hair-growth research and safety assessment to research into nanomaterials, surfactants, and the aging of hair and the scalp.
  20. FY2019-Q3RestatedAnnual report

    「Total research and development expenses for the cumulative third-quarter period were ¥269 million. There were no material changes in the status of the company's research and development activities during the cumulative third-quarter period.」

    The company stated that there were no material changes in research and development activities and recorded ¥269 million in research and development expenses.
  21. FY2019-Q2RestatedAnnual report

    「Total research and development expenses for the cumulative second-quarter period were ¥176 million. There were no material changes in the status of the company's research and development activities during the cumulative second-quarter period.」

    The company stated that there were no material changes in research and development activities, including hair-growth research and safety assessment, and recorded ¥176 million in research and development expenses.
  22. FY2019-Q1RestatedAnnual report

    「Total research and development expenses for the cumulative first-quarter period were ¥89 million. There were no material changes in the status of the company's research and development activities during the cumulative first-quarter period.」

    The company recorded ¥89 million in research and development expenses and stated that there were no material changes in research and development activities, including hair-growth research and safety assessment.
  23. FY2018-Q3RestatedAnnual report

    「Total research and development expenses for the cumulative third-quarter period were ¥232 million. There were no material changes in the status of the company's research and development activities during the cumulative third-quarter period.」

    The company recorded ¥232 million in research and development expenses and stated that there were no material changes in research and development activities, including hair-growth research and safety assessment.
  24. FY2018-Q2RestatedAnnual report

    「Total research and development expenses for the cumulative second-quarter period were ¥150 million. There were no material changes in the status of the company's research and development activities during the cumulative second-quarter period.」

    The company recorded ¥150 million in research and development expenses and stated that there were no material changes in research and development activities, including hair-growth research and safety assessment.
  25. FY2018-Q1RestatedAnnual report

    「Total research and development expenses for the cumulative first-quarter period were ¥72 million. There were no material changes in the status of the company's research and development activities during the cumulative first-quarter period.」

    The company recorded ¥72 million in research and development expenses and stated that there were no material changes in research and development activities, including hair-growth research and safety assessment.
  26. FY2017AdvancedAnnual report

    「The current priority areas in basic research are the following 3: research, with the cooperation of external research institutions and universities, into ① the hair-growth effects of nanoparticulate active ingredients and their effects on hair interiors, ② the operation of safety-assessment methods using 3D skin models, and ③ establishing an evaluation system for surfactant-induced itching.」

    The company identified research into hair growth, safety assessment using 3D skin models, and an evaluation system for surfactant-induced itching as priority areas, and incurred ¥286 million in research and development expenses.
  27. FY2017-Q3RestatedAnnual report

    「Total research and development expenses for the cumulative third-quarter period were ¥212 million. There were no material changes in the status of the company's research and development activities during the cumulative third-quarter period.」

    The company disclosed ¥212 million in research and development expenses and stated that there were no material changes in the status of its research and development activities.
  28. FY2017-Q2RestatedAnnual report

    「There were no material changes in the status of the company's research and development activities during the cumulative second-quarter period.」

    It states that there were no material changes in research and development activities, including hair-growth research and safety assessment.
  29. FY2017-Q1RestatedAnnual report

    「There were no material changes in the status of the company's research and development activities during the cumulative first-quarter period.」

    It states that there were no material changes in research and development activities, including hair-growth research and safety assessment.
  30. FY2016First statedAnnual report

    「Our current basic-research priorities are the following 3 areas, and we conduct research with the cooperation of external research institutions and universities: ① the hair-growth effects of nanoparticulating active ingredients and their effects inside the hair; ② methods for evaluating hair-growth effects through analysis of mRNA activity; and ③ implementation of safety-evaluation methods using 3D skin models.」

    Treats hair-growth research and safety evaluation using 3D skin models as medium- to long-term themes.
Moved together

"Development of New Products and Hair Color Products" moved the same way as this thread, in the same document, in 3 of its 30 moves.

333222★123456
  1. ★This thread
  2. 1Development of New Products and Hair Color Products3×
  3. 2Enhancing Shareholder Value Through Stock Splits and Share Repurchases3×
  4. 3Establishment of an Evaluation System for Surfactant-Induced Itching3×
  5. 4Slowing Overseas Economies and Stagnant Personal Consumption2×
  6. 5Seasonal concentration of results in the third quarter2×
  7. 6Developing Talent and Successors for the Next Generation2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Cota's next results are scheduled for 2026-11-05. Read the earnings preview It last moved in the Other Disclosures of 2026-06-11: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Hair-Growth Research and Safety Assessment Without Animal Testing | COTA CO.,LTD. (4923) | Komori